EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

T Cells

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Semin Cancer Biol.

Kumar P, Saini S, Prabhakar BS

doi: 10.1016/j.semcancer.

Further Publications Rheumatology

Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer

Arthritis Rheumatol

Cunningham-Bussel A, Wang J, Prisco LC, Martin LW, Vanni KMM, Zaccardelli A, Nasrallah M, Gedmintas L, MacFarlane LA, Shadick NA, Awad MM, Rahma O, LeBoeuf NR, Gravallese EM, Sparks JA

doi: 10.1002/art.41949

COMMENTED

Immunotherapy

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

★ 3 Recommended and commented by Prof. Dr Dr Sacha Rothschild, Faculty Member

Eur J Cancer

Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, Gérard CL, Latifyan S, Özdemir BC, Caikovski M, Pradervand S, Tavazzi E, Gatta R, Marandino L, Valabrega G, Aglietta M, Obeid M, Homicsko K, Mederos Alfonso NN, Zimmermann S, Coukos G, Peters S, Cuendet MA, Di Maio M, Michielin O

doi: 10.1016/j.ejca.2021.03.010

ImmunotherapyT Cells

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

J Autoimmun.

Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P

doi: 10.1016/j.jaut.2019.102310.

Melanoma and Skin Cancer

C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting

Melanoma Res

Lauwyck J, Beckwée A, Santens A, Schwarze JK, Awada G, Vandersleyen V, Aspeslagh S, Neyns B

doi: 10.1097/CMR.0000000000000748

Immunotherapy

Long-term immune-related adverse events after discontinuation of immunotherapy

Immunotherapy

Horisberger K, Portenkirchner C, Rickenbacher A, Biedermann L, Gubler C, Turina M

doi: 10.2217/imt-2020-0320

Immunotherapy

Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors

Eur J Cancer

Makarious D, Horwood K, Coward JIG

doi: 10.1016/j.ejca.2017.05.041.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Rheumatological complications of immune checkpoint inhibitor therapy

Rev Med Suisse.

Lazarou I, Fernandez E

doi: undefined.

T Cells

Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer

J Autoimmun

Calabrese LH, Caporali R, Blank CU, Kirk AD

doi: 10.1016/j.jaut.2020.102546

Related content

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting

Long-term immune-related adverse events after discontinuation of immunotherapy

Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors

Rheumatological complications of immune checkpoint inhibitor therapy

Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer